title: How to select an antifungal agent in critically ill patients.
abstract: Fungal infections are common in critically ill patients and are associated with increased morbidity and mortality. Candida spp are the most commonly isolated fungal pathogens. The last 2 decades have seen an increased incidence of fungal infections in critical illness and the emergence of new pathogenic fungal species and also the development of more effective (better bioavailability) and safer (less toxicity, fewer drug interactions) drugs. The distinction between colonization and infection can be difficult, and problems diagnosing infection may delay initiation of antifungal treatment. A number of factors have been identified that can help to distinguish patients at high risk for fungal infection. The antifungal agents that are most frequently used in the intensive care unit are the first- and second-generation azoles and the echinocandins; amphotericin B derivatives (mainly the liposomal agents) are less widely used because of adverse effects. The choice of antifungal agent in critically ill patients will depend on the aim of therapy (prophylaxis, pre-emptive, empiric, definitive), as well as on local epidemiology and specific properties of the drug (antifungal spectrum, efficacy, toxicity, pharmacokinetic/pharmacodynamic properties, cost). In this article we will review all these aspects and propose an algorithm to guide selection of antifungal agents in critically ill patients.
authors.affiliation: 2nd Department of Critical Care Medicine, Medical School, University of Athens, University Hospital ATTIKON, Athens, Greece.
authors.forename: George
authors.initials: G
authors.lastname: Dimopoulos
authors.forename: Anastasia
authors.initials: A
authors.lastname: Antonopoulou
authors.forename: Apostolos
authors.initials: A
authors.lastname: Armaganidis
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Vincent
mesh_terms: D000465:Algorithms; D000935:Antifungal Agents / Q000627:therapeutic use*; D016638:Critical Illness; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents
keywords: Echinocandins; Empiric therapy; Fungal antigens; Invasive fungal infections; Pre-emptive therapy; Prophylaxis